产品
编 号：F373727
分子式：C6H6N2O3
分子量：154.12
分子式：C6H6N2O3
分子量：154.12
产品类型
规格
价格
是否有货
50mg
528
In-stock
100mg
1012
In-stock
结构图
CAS No: 51037-30-0
产品详情
生物活性：
Acipimox (K-9321), a nicotinic acid analogue, is an antilipolytic compound. Acipimox stimulates leptin releas, inhibits lipolysis and suppresses systemic levels of free fatty acids (FFAs) and improves insulin sensitivity.
体内研究：
Acipimox (50 mg/kg; i.p.) significantly lowers circulating free fatty acid (FFA) and glucose in high-fat fed mice.Animal Model:Female C57BL/6J mice
Dosage:50 mg/kg
Administration:Intraperitoneal injection
Result:Reduced circulating levels of FFA and glucose after 3 h.
体外研究：
Acipimox (0-100 μM; 0-4 hours) enhances leptin release from adipocytes isolated from Sprague-Dawley rats in a time- and dose- dependent manner.Acipimox (10 mM) stimulats leptin release in adipocytes from Streptozotocin (STZ)-treated and Zucker diabetic fat (ZDF) rats.
Acipimox (K-9321), a nicotinic acid analogue, is an antilipolytic compound. Acipimox stimulates leptin releas, inhibits lipolysis and suppresses systemic levels of free fatty acids (FFAs) and improves insulin sensitivity.
体内研究：
Acipimox (50 mg/kg; i.p.) significantly lowers circulating free fatty acid (FFA) and glucose in high-fat fed mice.Animal Model:Female C57BL/6J mice
Dosage:50 mg/kg
Administration:Intraperitoneal injection
Result:Reduced circulating levels of FFA and glucose after 3 h.
体外研究：
Acipimox (0-100 μM; 0-4 hours) enhances leptin release from adipocytes isolated from Sprague-Dawley rats in a time- and dose- dependent manner.Acipimox (10 mM) stimulats leptin release in adipocytes from Streptozotocin (STZ)-treated and Zucker diabetic fat (ZDF) rats.
产品资料
Copyright©2015-2024 沪ICP备2022026524号-1
沪公网安备